|
|
Дата |
|---|
| 18.11.2026 |
| 17.11.2026 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
0.89
|
0.9033
|
0.8221
|
0.8163
|
0.9068
|
0.9031
|
|
|
757 190.57
|
2 872.00
|
|
0.82
|
0.85
|
0.7864
|
0.7507
|
0.8329
|
0.8223
|
|
|
670 727.64
|
3 397.00
|
|
0.78
|
0.805
|
0.8311
|
0.7718
|
0.8449
|
0.7915
|
|
|
534 548.76
|
2 301.00
|
|
0.8088
|
0.85
|
0.82
|
0.78011
|
0.8499
|
0.8499
|
|
|
626 658.34
|
2 866.00
|
|
0.82
|
0.84
|
0.8947
|
0.82
|
0.898
|
0.83
|
|
|
596 974.08
|
2 352.00
|
|
0.84
|
0.87
|
0.86
|
0.8501
|
0.9083
|
0.861
|
|
|
350 275.82
|
1 555.00
|
|
0.855
|
0.888
|
0.91
|
0.86
|
0.91
|
0.8601
|
|
|
382 111.11
|
2 937.00
|
|
0.90
|
0.95
|
0.94
|
0.8902
|
0.94
|
0.9088
|
|
|
222 205.09
|
1 714.00
|
|
0.90
|
0.93
|
0.9037
|
0.88
|
0.9301
|
0.9095
|
|
|
377 187.12
|
1 932.00
|
|
0.92
|
0.949
|
1.01
|
0.90
|
1.04
|
0.9081
|
|
|
887 654.45
|
2 099.00
|
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Показать все Скрыть| 20.08.2026 |
|
| 28.08.2024 |
|